Experts have discovered hidden potential in a class of cutting-edge cancer drugs, which they predict could soon have greater benefits in extending life.
New drugs, known as kinase inhibitors, have been found to work across types of breast, skin, lung and kidney cancer, and are among the most heralded of the new generation of cancer treatments.
Already 25 such drugs are in use and around 5,000 to 10,000 patients receive the drugs in the UK each year.
